Considering the relevance of MIF in patients suffering from autoimmune diseases such as SLE and RA, we are of the opinion that the presence of hapten-modified MIF in patients with ACD are worth exploring to investigate if haptenated MIF could be a general disease biomarker for the condition. This evidence concerns the gene MIF and rheumatoid arthritis.